Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on September 18, 2003, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

DrugSchedule
Cathinone (1235)I
Methcathinone (1237)I
Aminorex (1585)I
Alpha-ethyltryptamine (7249)I
Lysergic acid diethylamide (7315)I
Tetrahydrocannabinols (7370)I
4-Bromo-2,5-dimethoxy-amphetamine (7391)I
4-Bromo-2,5-dimethoxyphenethylamine (7392)I
2,5-Dimethoxyamphetamine (7396)I
3,4-Methylenedioxyamphetamine (7400)I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)I
3,4-Methylenedioxy-N-ethylamphetamine (7404)I
Start Printed Page 67480
3,4-Methylenedioxymethamphetamine (MDMA) (7405)I
1-[1-(2-thienyl)cyclohexyl]piperidine (TCP) (7470)I
Heroin (9200)I
Normorphine (9313)I
Amphetamine (1100)II
Methamphetamine (1105)II
1-Phenylcyclohexylamine (7460)II
Phencyclidine (7471)II
Cocaine (9041)II
Codeine (9050)II
Diprenorphine (9058)II
Ecgonine (9180)II
Levomethorphan (9210)II
Levorphanol (9220)II
Meperidine (9230)II
Metazocine (9240)II
Methadone (9250)II
Morphine (9300)II
Thebaine (9333)II
Levo-alphacetylmethadol (9648)II
Carfentanil (9743)II
Fentanyl (9801)II

The firm plans to manufacture the listed controlled substances for laboratory reference standards and neurochemicals.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than February 2, 2004.

Start Signature

November 14, 2003.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. 03-29963 Filed 12-01-03; 8:45 am]

BILLING CODE 4410-09-M